Dermapharm Holding SE (DMP.DE) Tuesday reported preliminary results for the first half. The German pharmaceutical company also confirmed its full-year outlook.
Dermapharm posted preliminary EBITDA, or earnings before interest, taxes, depreciation, and amortization of 144.9 million euros for the first half, 1.4% lower than 147 million euros in the comparable quarter last year.
On an adjusted basis, EBITDA decreased 3.3% year-on-year to 148 million euros.
Revenue for the period declined 0.7% to 574.5 million euros from 578.5 million euros in the previous year.
For the full year, the company continues to expect revenue in the range of 1.160 billion euros - 1.200 billion euros. Adjusted EBITDA is expected between 322 million euros and 332 million euros.
Complete half-year results are scheduled to be reported on August 26.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.